BridgeBio Pharma (NASDAQ:BBIO) CFO Thomas Trimarchi Sells 13,600 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Thomas Trimarchi sold 13,600 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the transaction, the chief financial officer directly owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. The trade was a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO traded down $1.92 during midday trading on Wednesday, hitting $73.93. 2,365,520 shares of the stock were exchanged, compared to its average volume of 3,243,876. The business’s 50-day moving average price is $75.70 and its 200 day moving average price is $63.72. BridgeBio Pharma, Inc. has a 12 month low of $28.33 and a 12 month high of $84.94. The stock has a market capitalization of $14.25 billion, a price-to-earnings ratio of -17.69 and a beta of 1.13.

Institutional Trading of BridgeBio Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Strs Ohio raised its holdings in BridgeBio Pharma by 1.1% in the third quarter. Strs Ohio now owns 18,600 shares of the company’s stock worth $966,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of BridgeBio Pharma by 28.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after buying an additional 227 shares in the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of BridgeBio Pharma by 22.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock valued at $54,000 after buying an additional 228 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in BridgeBio Pharma by 4.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock valued at $396,000 after buying an additional 244 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on BBIO shares. HC Wainwright lifted their price objective on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Wells Fargo & Company upped their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Finally, JPMorgan Chase & Co. increased their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.05.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.